Source: yahoo_news
Source ID: yahoo:06380281957c385b783691bda8b379ad:CORT
URL: https://finance.yahoo.com/healthcare/articles/corcept-reports-positive-results-phase-120000347.html?.tsrc=rss
Symbol: (CORT)
Published: 2026-10-26 08:00:00 EDT
Time precision: minute
Title: Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif., October 26, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company’s Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant